A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Official Title
-----------------
The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study

Conditions
-----------------
Diffuse Large B-Cell Lymphoma

Intervention / Treatment
-----------------
* Drug: Polatuzumab Vedotin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be diagnosed as DLBCL Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail Cohort 3: relapse or refractory to previous treatment Exclusion Criteria: Participant who currently participates in or with plan to participate in any interventional clinical trial Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Unfit/frail participants with DLBCL who are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). | Drug: Polatuzumab Vedotin<br>* Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.<br>* Other names: POLIVY ®;|
| Cohort 2<br>Participants with DLBCL who can not be classified into unfit/frail but are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). | Drug: Polatuzumab Vedotin<br>* Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.<br>* Other names: POLIVY ®;|
| Cohort 3<br>Participants with relapsed or refractory (R/R) DLBCL who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). | Drug: Polatuzumab Vedotin<br>* Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.<br>* Other names: POLIVY ®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cohorts 1 and 2: Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | At 24 months | 
| Cohort 3: PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | Baseline up to end of study (EOS) (approximately 38 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cohort 3: PFS24 Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | At 24 months | 
| Cohorts 1, 2 and 3: Time to Next Treatment (TTNT) |  | From the start of polatuzumab treatment to the initiation of next-line treatment (up to approximately 38 months) | 
| Cohorts 1, 2 and 3: Complete Response Rate (CRR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | Baseline up to EOS (approximately 38 months) | 
| Cohorts 1, 2 and 3: Overall Response Rate (ORR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | Baseline up to EOS (approximately 38 months) | 
| Cohorts 1 and 2: Disease Control Rate (DCR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | Baseline up to EOS (approximately 38 months) | 
| Cohorts 1, 2 and 3: Duration of Response (DoR) |  | From the date of the first occurrence of a documented CR or partial response (PR) to the date of progression, relapse, or death from any cause, whichever occurs first (up to approximately 38 months) | 
| Cohorts 1 and 2: Disease Free Survival (DFS) |  | From the date of the first occurrence of a documented CR, to the date of relapse or death from any cause, whichever occurs first (up to approximately 38 months) | 
| Cohorts 1 and 2: Event Free Survival (EFS) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma |  | From the start of polatuzumab treatment to any treatment failure including disease progression, relapse, initiation of new antilymphoma therapy (NALT), or death from any cause, which occurs first (up to approximately 38 months) | 
| Cohorts 1, 2 and 3: Overall Survival (OS) |  | From the start of polatuzumab treatment until the date of death from any cause (up to approximately 38 months) | 
| Cohorts 1, 2 and 3: Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | AEs will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | Up to EOS (approximately 38 months) |